| Name | Title | Contact Details |
|---|
Memorial Hospital at Gulfport is a not-for-profit medical complex in Gulfport, Mississippi, jointly owned by the City of Gulfport and Harrison County. Memorial is one of the most comprehensive healthcare systems in the state, licensed for 303 beds, including a state-designated Level II Trauma Center, two outpatient surgery centers, satellite outpatient diagnostic and rehabilitation centers and more than 95 Memorial Physician Clinics. Memorial offers several of the region`s most comprehensive clinical programs, such as emergency medicine; women and children services; orthopedic services; cardiovascular services; neurosciences and oncology. Additionally, Memorial provides medical specialties unique to the coast which include a Level III Neonatal ICU and Mississippi`s first nationally certified Primary Stroke Center. Memorial offers 3D imaging and advanced surgical techniques, including the robotic assisted Specialty Surgery System. Memorial is accredited by The Joint Commission, the Commission on Cancer, the College of American Pathologists and the American College of Radiology.
Les Restaurants Pacini is a La Prairie, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medaxial is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hillcrest Healthcare System is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Knoxville, TN. To find more information about Hillcrest Healthcare System, please visit www.hillcrest.com
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III